Stoke Therapeutics (STOK) has drawn fresh investor attention after recent share price moves, with the stock showing mixed short term performance and gains over the past 3 months and year.

At a share price of $33.08, Stoke Therapeutics has seen a 1 day share price return of 1.10%, while its 1 year total shareholder return of 243.51% reflects recent momentum following a slower multi year record.

If you are comparing Stoke with other high growth healthcare names, this could be a moment to scan for more focused opportunities through our healthcare AI stock screener, starting with 33 healthcare AI stocks.

That kind of multi year return, recent revenue growth and a market value of about US$2.0b raises a key question: is Stoke Therapeutics still trading below what its growth prospects imply, or has the market already priced them in?

Most Popular Narrative: 3.4% Undervalued

Analysts following Stoke Therapeutics see fair value close to $34.25, only slightly above the recent $33.08 price. This keeps expectations tight around future execution.

The shift toward disease-modifying therapies in severe epilepsies raises the regulatory and evidentiary bar. Any delay, additional data requirements, or failure to show clear differentiation versus emerging competitors could push out potential launch timing and limit peak revenue.

Want to understand how this narrative still lands on a higher fair value? The heart of the model is a sharp reset in future revenues, paired with a rich profit margin and a premium earnings multiple that assumes Stoke will earn treatment pricing power in a complex rare disease market.

Result: Fair Value of $34.25 (UNDERVALUED)

However, this hinges on Phase 3 data for zorevunersen and on long, costly late stage neurology trials, where safety findings or regulatory delays could quickly challenge today’s assumptions.

Next Steps

With sentiment split between Stoke’s recent share price strength and the execution hurdles ahead, this is a good moment to review the facts and move quickly to your own view. Start with the 3 key rewards and 2 important warning signs.

Looking for more investment ideas?

If Stoke has caught your eye, do not stop here. A few minutes with the right stock lists can surface opportunities you would not want to miss.

• Hunt for quality at a discount by scanning companies that screen as 51 high quality undervalued stocks.
• Prioritise resilience by reviewing 67 resilient stocks with low risk scores so you can focus on businesses with steadier risk profiles.
• Spot earlier stage opportunities by checking 24 elite penny stocks with strong financials that pair smaller market caps with stronger fundamentals.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.